Compare ITRM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRM | AEON |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Ireland | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 25.8M |
| IPO Year | 2018 | N/A |
| Metric | ITRM | AEON |
|---|---|---|
| Price | $0.03 | $0.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.00 | $7.20 |
| AVG Volume (30 Days) | ★ 30.9M | 130.6K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $947.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.43 |
| 52 Week High | $1.16 | $1.45 |
| Indicator | ITRM | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 26.10 | 41.62 |
| Support Level | N/A | $0.91 |
| Resistance Level | $0.39 | $1.12 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 3.34 | 34.33 |
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.